Arcturus Therapeutics Holdings Inc. (ARCT) Ownership
ARCT ownership summary
as of October 17, 2026- Institutions
- 77.3% of shares outstanding
- Insiders
- 7.99% of shares outstanding
- Shares outstanding
- 28.4M
- Float
- 26.2M shares available to trade
- Short interest
- 23.54% 5.4M shares short
- Days to cover
- 5.88 short interest down 1.6% vs prior month
- Institutions 77.25%
- Insiders 7.99%
- Other investors 14.76%
ARCT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Federated Hermes Inc | 11.62% | 3.3M | $34.2M | — | June 30, 2026 |
| 2 | ARK Investment Management LLC | 10.21% | 2.9M | $30.0M | +132,117 (+4.8%) | June 30, 2026 |
| 3 | BlackRock Inc | 9.20% | 2.6M | $27.0M | +731 (+0.0%) | June 30, 2026 |
| 4 | Sumitomo Mitsui Trust Group Inc | 6.91% | 2.0M | $20.3M | −325,812 (−14.2%) | June 30, 2026 |
| 5 | Amova Asset Management Americas, Inc | 6.90% | 2.0M | $20.3M | −328,477 (−14.4%) | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 3.92% | 1.1M | $11.5M | +7,936 (+0.7%) | June 30, 2026 |
| 7 | Two Sigma Investments LLC | 3.84% | 1.1M | $11.3M | +9,353 (+0.9%) | June 30, 2026 |
| 8 | Vanguard Portfolio Management, LLC | 3.35% | 952K | $9.8M | −26,347 (−2.7%) | June 30, 2026 |
| 9 | Geode Capital Management, LLC | 2.44% | 694K | $7.2M | +32,732 (+5.0%) | June 30, 2026 |
| 10 | AQR Capital Management LLC | 2.37% | 675K | $7.0M | +513,736 (+318.5%) | June 30, 2026 |
| 11 | Jacobs Levy Equity Management, Inc. | 2.28% | 648K | $6.7M | +448,783 (+225.8%) | June 30, 2026 |
| 12 | State Street Corp | 2.00% | 570K | $5.9M | +25,735 (+4.7%) | June 30, 2026 |
| 13 | UBS Group AG | 1.73% | 491K | $5.1M | +32,355 (+7.1%) | June 30, 2026 |
| 14 | D. E. Shaw & Co LP | 1.38% | 392K | $4.1M | +140,324 (+55.7%) | June 30, 2026 |
| 15 | Empire Life Investments Inc | 1.29% | 366K | $3.8M | −17,276 (−4.5%) | June 30, 2026 |
| 16 | Hennion & Walsh Asset Management Inc | 1.22% | 346K | $3.6M | +66,528 (+23.8%) | June 30, 2026 |
| 17 | Millennium Management LLC | 1.19% | 337K | $3.5M | −141,561 (−29.6%) | June 30, 2026 |
| 18 | The Goldman Sachs Group Inc | 1.09% | 310K | $3.2M | +111,182 (+56.0%) | June 30, 2026 |
| 19 | BNP Paribas Arbitrage, SA | 0.92% | 262K | $2.7M | +66,929 (+34.3%) | June 30, 2026 |
| 20 | Charles Schwab Investment Management Inc | 0.81% | 232K | $2.4M | +15,128 (+7.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 14 holders added 1.6M shares and 5 cut 839K.
ARCT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF | 9.78% | 2.8M | $28.7M | +6,792 (+0.2%) | September 30, 2026 |
| 2 | Federated Hermes Kaufmann R | 7.29% | 2.1M | $21.4M | — | June 30, 2026 |
| 3 | Amova ARK Pstv Chg Innovt P JPY Acc | 5.34% | 1.5M | $15.7M | −87,852 (−5.5%) | August 31, 2026 |
| 4 | Federated Hermes Kaufmann Small Cap A | 4.18% | 1.2M | $12.3M | — | June 30, 2026 |
| 5 | Vanguard MStar Total Stk Mkt Idx Invest | 2.80% | 797K | $8.2M | — | August 31, 2026 |
| 6 | iShares Russell 2000 ETF | 2.46% | 700K | $7.2M | −8,064 (−1.1%) | September 30, 2026 |
| 7 | Fidelity Small Cap Index | 1.03% | 292K | $3.0M | +1,410 (+0.5%) | July 31, 2026 |
| 8 | Vanguard Explorer Inv | 1.00% | 286K | $3.0M | — | June 30, 2026 |
| 9 | iShares Russell 2000 Value ETF | 0.90% | 255K | $2.6M | +388 (+0.2%) | September 30, 2026 |
| 10 | Vanguard Strategic Small-Cap Equity Inv | 0.89% | 254K | $2.6M | — | June 30, 2026 |
| 11 | Empire Life American Value Cl A | 0.78% | 222K | $2.3M | — | June 30, 2026 |
| 12 | iShares Biotechnology ETF | 0.74% | 210K | $2.2M | −1,592 (−0.8%) | September 30, 2026 |
| 13 | JPM Thmtcs Gentc Thrps C2 dist USD | 0.63% | 179K | $1.8M | +2,007 (+1.1%) | August 31, 2026 |
| 14 | Vanguard Russell 2000 ETF | 0.54% | 154K | $1.6M | +3,632 (+2.4%) | August 31, 2026 |
| 15 | ARK Genomic Revolution ETF A USD Acc | 0.54% | 152K | $1.6M | — | September 30, 2026 |
| 16 | Fidelity Select Biotechnology | 0.53% | 150K | $1.5M | +149,500 (0.0%) | August 31, 2026 |
| 17 | Fidelity Extended Market Index | 0.52% | 147K | $1.5M | −16,123 (−9.9%) | August 31, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.48% | 136K | $1.4M | +90 (+0.1%) | September 30, 2026 |
| 19 | Vanguard Strategic Equity Inv | 0.42% | 118K | $1.2M | — | June 30, 2026 |
| 20 | BSF Systematic US Eq Abs Ret A2 USD | 0.36% | 103K | $1.1M | +44,559 (+75.7%) | December 31, 2025 |
Funds report holdings monthly or quarterly; dates differ by fund.
ARCT insider transactions
latest 13| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2024-10-15 | Pad Chivukula | Sell | $20.76 | 12,000 | $249,120 |
| 2024-06-05 | Pad Chivukula | Sell | $45.00 | 114 | $5,130 |
| 2024-06-03 | Pad Chivukula | Sell | $40.01 | 26,000 | $1.0M |
| 2024-03-25 | Pad Chivukula | Sell | $35.02 | 17,435 | $610,574 |
| 2024-03-19 | Pad Chivukula | Sell | $35.01 | 8,565 | $299,861 |
| 2023-11-01 | Pad Chivukula | Sell | $18.72 | 5,000 | $93,600 |
| 2023-10-02 | Pad Chivukula | Sell | $25.61 | 5,000 | $128,050 |
| 2023-09-01 | Pad Chivukula | Sell | $31.45 | 5,000 | $157,250 |
| 2023-07-14 | Keith C Kummerfeld | Sell | $35.00 | 6,968 | $243,880 |
| 2023-07-14 | Pad Chivukula | Sell | $35.01 | 25,000 | $875,250 |
| 2023-07-03 | Pad Chivukula | Sell | $28.75 | 5,000 | $143,750 |
| 2023-05-10 | Pad Chivukula | Sell | $30.00 | 17,075 | $512,250 |
| 2023-05-01 | Pad Chivukula | Sell | $25.93 | 5,000 | $129,650 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ARCT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ARCT
Institutional investors own 77.3% of Arcturus Therapeutics's shares and insiders 7.99%. The largest holder is Federated Hermes Inc with 11.62% of the shares (3.3M), as of June 30, 2026. Among the top 20 institutions, 14 added shares and 5 reduced their stake in the latest filings. Short interest is 23.54% of the float, or 5.88 days of average trading volume. The share count rose 851.0% since 2014.
Related: ARCT analyst forecast, ARCT key metrics. See the ARCT stock overview for the latest quote and news.
ARCT ownership FAQ
Who owns the most Arcturus Therapeutics stock?
The largest shareholders of Arcturus Therapeutics are Federated Hermes Inc (11.62%), ARK Investment Management LLC (10.21%), BlackRock Inc (9.20%), Sumitomo Mitsui Trust Group Inc (6.91%), Amova Asset Management Americas, Inc (6.90%).
What percentage of Arcturus Therapeutics is owned by institutions?
Institutions hold 77.3% of Arcturus Therapeutics's shares outstanding; insiders hold 7.99%.
Which funds own Arcturus Therapeutics?
The largest fund holders of Arcturus Therapeutics are ARK Genomic Revolution ETF (9.78%), Federated Hermes Kaufmann R (7.29%), Amova ARK Pstv Chg Innovt P JPY Acc (5.34%), Federated Hermes Kaufmann Small Cap A (4.18%), Vanguard MStar Total Stk Mkt Idx Invest (2.80%).
What is Arcturus Therapeutics's short interest?
5.4M shares of Arcturus Therapeutics were sold short, 23.54% of the float; at the average daily volume it would take 5.88 days to cover.
Are insiders buying or selling Arcturus Therapeutics?
Of the latest 13 reported insider transactions in Arcturus Therapeutics (since May 1, 2023), 0 were purchases and 13 were sales.
How many shares of Arcturus Therapeutics are outstanding?
Arcturus Therapeutics has 28.4M shares outstanding, of which 26.2M are in the public float.